Famotidine Articles
Americans with heartburn paying too much for Nexium's 'Purple Pill,' claims Consumer Reports
30 October 2009
Japan stock market week to June 8, 2009
9 June 2009
Azur buys four drugs from UCB
19 January 2009
Horizon settles Ph III US HZT-501 trial design
15 January 2007
Horizon completes $21M financing to advance NSAIDs pipeline
15 January 2007
Perrigo's generic famotidine cleared in USA
2 October 2006
Yamanouchi overcomes drug pric cuts
22 November 2004
Richter Gedeon's nine-month profit grows 7%
22 November 2004
Richter Gedeon's nine-month profit grows 7%
22 November 2004
3% underlying sales rise at Yamanouchi
23 August 2004
Fujisawa/Yamanouchi to set up Zepharma
31 May 2004
Weak core products sales at Yamanouchi
31 May 2004
Tokyo pharma stocks - week to April 19
26 April 2004
Tokyo pharma stocks - week to March 8
15 March 2004
Japan announces 4.2% average Rx price cut
15 March 2004
Sankyo's Mevalotin retains number one spot in Japan
2 February 2004
Eisai's pravastatin generic sluggish
5 January 2004
Yamanouchi in line with revised forecast
24 November 2003
Japanese drug firms "a more attractive short term proposition than US or European"
29 September 2003
Tokyo pharma stocks - week to June 30
7 July 2003
Yamanouchi's FY2003 operating income up 12%
26 May 2003
Richter Gedeon files to protect famotidine in Japan
10 February 2003
US TV exposes "4,000% generic markups"
29 July 2002
Tokyo pharma stocks - week to July 8
15 July 2002
Tokyo pharma stocks - week to May 20
27 May 2002
Hungary's Richter suing Japanese firms
15 April 2002
Tokyo pharma stocks - week to April 8
15 April 2002
Drugmakers in Japan seek Rx-OTC switches
25 February 2002
Five key products continue to drive Merck & Co sales in 2001
28 January 2002
Lipitor boosts Yamanouchi sales
12 November 2001
Stock Commentary - New York
25 October 2001
Merck & Co turnover up 13% but Vioxx sales are slowing down
19 October 2001
Dr Reddy's to launch famotidine in USA
24 August 2001
180-day exclusivity for Teva's famotidine
6 June 2001
Japan pharma stock market week to May 21
23 May 2001
Review of Indian pharma 1st-qtr results
11 May 2001
Tokyo pharma stocks week to April 30
2 May 2001
Yamanouchi sets out five-year strategy
30 April 2001
Generics firms take on Merck & Co's Pepcid
17 April 2001
Mylan gets tentative go-ahead for generic Pepcid
8 February 2001
Stock Commentary - Tokyo
25 January 2001
Indian price moves for 45 formulations
23 January 2001
Merck & Co wins six-month exclusivity for Pepcid
23 November 2000
Yamanouchi sales up on forecasts
13 November 2000
J&J gets approval for chewable Pepcid
17 October 2000
Spanish drugmakers adapt to advent of generics regime
15 September 2000
Yamanouchi to sell new Gaster drug
20 June 2000
Yamaanouci looks to Lipitor for future growth
24 May 2000
Norwegian OTC sales "grew 2% in 1998"
10 February 2000
Stock Commentary Tokyo
20 January 2000
Yamanouchi's Gaster weathers patent expiry
20 January 2000
Yamanouchi watching Lipitor developments
24 November 1999
Dumping causes key Indian bulk drug prices to plunge
12 November 1999
Stock Commentary Tokyo
19 August 1999
Stock Commentary Tokyo
5 August 1999
Merck & Co pulls out of Chugai OTC JV
21 July 1999
OTC ads "beat DTC for product recall"
14 July 1999
Stock Commentary Tokyo
24 June 1999
Stock Commentary Tokyo
17 June 1999
Stock Commentary Tokyo
10 June 1999
Stock Commentary Tokyo
3 June 1999
Stock Commentary Tokyo
27 May 1999
Yamanouchi plans Pepcid patent extension
26 May 1999
Yamanouchi sales fall 11.3% in latest year
25 May 1999
Stock Commentary Tokyo
13 May 1999
Stock Commentary Tokyo
11 February 1999
Merck disappointment as highly-touted antidepressant stalls
26 January 1999
Merck & Co Wins Pepcid Patent Fight
14 October 1998
Rx-To-OTC Switches "Not Working Except In USA"
6 October 1998
Japan's Yamanouchi Accused Of Tax Evasion
2 July 1998
Pharmaceutical Companies Face Up To The Future
15 June 1998
OTC Drug Markets In East And Southeast Asia
3 April 1998
FDA Clears GW's Effervescent Zantac
5 March 1998
Stock Commentary Tokyo
5 February 1998
Yamanouchi Looks For Gaster Successor
22 January 1998
Australia Excludes SSRIs From Final TGP Scheme
17 December 1997
Yamanouchi 1st Half Net Income Up 15%
14 November 1997
Solid Growth For US Firms Despite Strong $
24 July 1997
OTC Famotidine In Japan
12 June 1997
Strong Earnings Growth At Yamanouchi
30 May 1997
Merck & Co's Propecia Shows Promise In Hair Loss
26 March 1997
TOKYO STOCK COMMENT
17 February 1997
US H2 Blocker Boom Forecast To Slow Down
27 January 1997
Astra's Losec "World's No One Drug In 1998-2000"
16 December 1996
Good Japanese Interim Results, Despite Price Cuts
25 November 1996
US Quarterly Results Show Improvements
4 November 1996
H2 Blockers' US Sales Boom Set To Slow?
21 October 1996
The Role Of Managed Care In Rx-To-OTC Switches
21 October 1996
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
